Watch Imagion CEO Bob Proulx discuss the opportunity for MagSense® Imaging on Switzer’s CEO Masterclass:
Today’s imaging technologies are limited in their ability to differentiate benign lesions from cancerous tumors, resulting in additional testing, resources and added risk. Imagion Biosystems’ MagSense technology has the opportunity to change this.
Imagion’s President & CEO Bob Proulx recently appeared on Switzer’s CEO Masterclass. In this video, watch Bob explain to Peter Switzer the unique properties of Imagion’s nanoparticle platform, the commercial opportunity ahead and its recent milestones achieved on the path to the clinic.
Watch the full interview by clicking the image above.
